普纳替尼剂量范围研究:慢性期慢性髓性白血病随机开放标签2期试验
本研究为随机开放标签2期试验,纳入对至少2种TKI耐药/不耐受或携带BCR-ABL1 T315I突变的CP-CML成人患者,1:1:1随机接受普纳替尼45、30或15 mg每日一次起始,45和30 mg组获应答后减至15 mg。主要终点12个月应答率在45、30、15 mg组分别为44.1%、29.0%、23.1%,3级及以上AOE分别为5、5、3例,45 mg起始并应答后减量至15 mg获最佳获益/风险。
要点
- 45 mg起始、应答后减至15 mg的方案获益/风险最佳
- 12个月应答率45 mg组44.1%,30 mg组29.0%,15 mg组23.1%
- 3级及以上治疗中出现AOE在45、30、15 mg组分别为5、5、3例
核心结论
- 在高度耐药的CP-CML人群中所有起始剂量组均显示获益,45 mg起始并在获应答后减至15 mg的方案获益/风险最佳。
研究设计与样本
- 随机、开放标签2期试验,纳入对至少2种BCR-ABL1 TKI耐药或不耐受或携带BCR-ABL1 T315I突变的CP-CML成人患者。
- 2015年8月至2019年5月共283例患者按1:1:1随机分配至普纳替尼45、30、15 mg每日一次组,282例接受治疗(每组94例),数据截止2020年5月31日。
- 45和30 mg组患者在BCR-ABL1IS转录水平≤1%时减量至15 mg,主要终点为12个月时应答。
主要发现
- 主要终点(98.3% CI)在45 mg组为44.1%(31.7-57.0),30 mg组为29.0%(18.4-41.6),15 mg组为23.1%(13.4-35.3)。
- 独立确认的3级及以上治疗中出现AOE在45、30、15 mg组分别发生于5、5、3例患者。
关键数值与推荐
- 45 mg组主要终点44.1%(98.3% CI 31.7-57.0),30 mg组29.0%(18.4-41.6),15 mg组23.1%(13.4-35.3)。
- 45和30 mg组在BCR-ABL1IS≤1%时减量至15 mg。
- 3级及以上治疗中出现AOE例数:45 mg组5例、30 mg组5例、15 mg组3例。
临床怎么用
- 对多线TKI耐药或不耐受的CP-CML患者,可考虑普纳替尼45 mg起始,获BCR-ABL1IS≤1%应答后减至15 mg以优化获益/风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In PACE (Ponatinib Ph+ ALL and CML Evaluation), a phase 2 trial of ponatinib that included patients with chronic-phase chronic myeloid leukemia (CP-CML) resistant to multiple prior tyrosine kinase inhibitors (TKIs), ponatinib showed deep and durable responses, but arterial occlusive events (AOEs) emerged as notable adverse events. Post hoc analyses indicated that AOEs are dose dependent. We assessed the benefit/risk ratio across 3 ponatinib starting doses in the first prospective study to evaluate a novel, response-based, dose-reduction strategy for TKI treatment. Adults with CP-CML resistant to or intolerant of at least 2 prior BCR-ABL1 TKIs or with a BCR-ABL1 T315I mutation were randomly assigned 1:1:1 to 3 cohorts receiving ponatinib 45, 30, or 15 mg once daily. In patients who received 45 or 30 mg daily the dose was reduced to 15 mg upon response (BCR-ABL1IS transcript levels ≤1%). The primary end point was response at 12 months. From August 2015 through May 2019, 283 patients were randomly assigned to the cohorts: 282 (94 per dose group) received treatment (data cutoff, 31 May 2020). The primary end point (98.3% confidence interval) was achieved in 44.1% (31.7-57.0) in the 45-mg cohort, 29.0% (18.4-41.6) in the 30-mg cohort, and 23.1% (13.4-35.3) in the 15-mg cohort. Independently confirmed grade 3 or above treatment-emergent AOEs occurred in 5, 5, and 3 patients in the 45-, 30-, and 15-mg cohorts, respectively. All cohorts showed benefit in this highly resistant CP-CML population. Optimal benefit/risk outcomes occurred with the 45-mg starting dose, which was decreased to 15 mg upon achievement of a response. This trial is registered on www.clinicaltrials.gov as NCT02467270.
引用
- Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021. PMID: 34407543. doi:10.1182/blood.2021012082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。